Can-Fite to Present at Rodman & Renshaw Global Investment Conference on September 9, 2013
September 03 2013 - 1:38PM
Marketwired
Can-Fite BioPharma (TASE: CFBI), (PINKSHEETS:
CANFY), a biotechnology company with a pipeline of proprietary
small molecule drugs that address inflammatory and cancer diseases,
announced today that the Company's CEO, Dr. Pnina Fishman, will
present at the Annual Rodman & Renshaw Global Investment
Conference, Sponsored by H.C. Wainwright & Co. The conference
is being held September 8-10, 2013, at the Millennium Broadway
Hotel in New York City.
Dr. Fishman is scheduled to present an overview of Can-Fite to
investors on Monday, September 9th at 4:05 pm ET in room 7.02, 7th
floor.
Investors or journalists may request a one-on-one meeting with
Can-Fite's management by contacting Robert Haag at 1-866-976-IRTH
(4784) or canfy@irthcommunications.com.
Can-Fite is currently conducting Phase II and Phase III trials
in the U.S., Europe and Israel for five indications in cancer,
autoimmune inflammatory disease, and ophthalmology, which together
serve multi-billion dollar markets. The Company's CR102 has been
granted Orphan Drug Designation by the U.S. Food and Drug
Administration for the treatment of liver cancer. Can-Fite also
owns 82% of OphthaliX Inc., which is currently traded on the U.S.
markets (OTCQB: OPLI) (OTCQB: OPLID).
About Can-Fite Biopharma Ltd.
Can-Fite Biopharma Ltd is an Israeli public company, the
ordinary shares of which are traded on the Tel Aviv Stock Exchange
(TASE: CFBI). American Depository Receipts of the company are
traded on the over-the-counter market (PINKSHEETS: CANFY). The
company, which commenced business activity in 2000, was founded by
Pnina Fishman, Ph.D., researcher in the Rabin Medical Center, and
Ilan Cohn Ph.D., patent attorney and senior partner at Reinhold
Cohn Patent Attorneys. Pnina Fishman serves as CEO of the company.
The company was founded on the basis of Fishman's scientific
findings, and is focused on the development of small molecule
orally bioavailable drugs, ligands to the A3 adenosine receptor.
The latter mediates anti-inflammatory and anti-cancer effects and
is suggested as a biological predictive marker. The company's lead
drug, CF101, is in clinical development for the treatment of
autoimmune inflammatory diseases. The CF102 drug candidate is being
developed for the treatment of liver diseases. Can-Fite has a
wealth of clinical experience: to date, more than 700 patients have
participated in clinical trials conducted by the company. Can-Fite
previously licensed its activity in the ophthalmic field to
OphthaliX Inc., in which it holds a controlling interest (OTCQB:
OPLI) (OTCQB: OPLID).
Safe Harbor Statement
Any statements in this press release that relate to the
Company's expectations are forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act. The
Private Securities Litigation Reform Act of 1995 (PSLRA)
implemented several significant substantive changes affecting
certain cases brought under the federal securities laws, including
changes related to pleading, discovery, liability, class
representation and awards fees. Since this information may involve
risks and uncertainties and are subject to change at any time, the
Company's actual results may differ materially from expected
results. Additional risks associated with Can-Fite's business can
be found in its periodic filings with the Tel Aviv Stock
Exchange.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: IRTH Communications Robert Haag Email Contact
1-866-976-IRTH (4784)